"Methylene Bridge" to 5-HT 3 Receptor Antagonists: Conformationally Constrained Phenylguanidines

5Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT 3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazolines (such as A6CDQ; 1) results in their conversion to 5-HT 3 receptor antagonists. We examined the structure-activity relationships of 1. Replacement/removal of any of the guanidinium nitrogen atoms of 1 resulted in decreased affinity. All three nitrogen atoms of 1 are necessary for optimal binding affinity at 5-HT 3 receptors. Introduction of substituents as small as an N2-methyl group abolishes affinity. The results are consistent with homology modeling/docking studies and binding data from site-directed mutagenesis studies. Introducing a "methylene bridge" to the arylguanidine structure, regardless of its functional activity, results in a 5-HT 3 receptor antagonist.

Cite

CITATION STYLE

APA

Abdelkhalek, A. S., Alley, G. S., Alwassil, O. I., Khatri, S., Mosier, P. D., Nyce, H. L., … Dukat, M. (2019). “Methylene Bridge” to 5-HT 3 Receptor Antagonists: Conformationally Constrained Phenylguanidines. ACS Chemical Neuroscience, 10(3), 1380–1389. https://doi.org/10.1021/acschemneuro.8b00431

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free